Document:

Amendment No. 4 to License Agreement

 EXHIBIT 10.4 
 CV Therapeutics, Inc. 
 requests that the marked portions of the exhibit be granted confidential
treatment 
 under Rule 24b-2 of the Securities Exchange Act of 1934, as amended. 
 LICENSE AGREEMENT 
 AMENDMENT NO. 4 

THIS AMENDMENT NO. 4 TO THE LICENSE
AGREEMENT (“Fourth Amendment”) is made and entered into effective as of June 20, 2006 (“Fourth Amendment Date”) by and between ROCHE PALO ALTO LLC (successor in
interest by merger to SYNTEX (U.S.A.) INC.) (“Roche”), having offices at 3431 Hillview Avenue, Palo Alto, California 94304, and CV THERAPEUTICS, INC. (“CVT”), having an
address at 3172 Porter Drive, Palo Alto, California 94304. Capitalized Terms used in the Fourth Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the License Agreement. 
 RECITALS 
 Roche and CVT entered into the
License Agreement effective March 27, 1996 (“License Agreement”) and entered into three Amendments to the License Agreement effective July 3, 1997, November 30, 1999, and March 25, 2005, respectively
(“Amendments”). The License Agreement as amended by the Amendments and this Fourth Amendment shall constitute the “Agreement.” 
 The
parties now wish to amend the Agreement to change the scope of CVT’s rights under the license to the Syntex Patent Rights and Syntex Know-How, to add additional milestone payments and otherwise amend the Agreement as expressly set forth herein.

 NOW, THEREFORE, in consideration of the mutual promises contained herein, the sufficiency of which is hereby acknowledged, Roche and CVT now wish to amend
the Agreement as follows effective as of the Fourth Amendment Date: 
 1. Amendment of Section 1.7. Section 1.7 of the License Agreement is
hereby amended and replaced in its entirety with the following new Section 1.7: 
 “CVT Territory” shall mean all countries in
the world. 
 2. Amendment of Section 1.9. Section 1.9 of the License Agreement is hereby amended and replaced in its entirety with the
following new Section 1.9: 
 “Licensed Product(s)” shall mean human therapeutic product(s) containing any Licensed Compound as
an active ingredient, for any and all indications, in such formulations and modes of administration as determined by CVT. 
 3. Amendment of
Section 1.11. Section 1.11 of the License Agreement is hereby amended by deleting the phrase “for use in Cardiovascular Indications” from the end of the section. 
 4. Amendment of Section 2.1. Section 2.1 of the License Agreement is hereby amended and replaced in its entirety with the following new Section 2.1: 
 Syntex herewith grants to CVT under the Syntex Patent Rights and Syntex Know-How: 
  

	 	a)	an exclusive right and license to develop and register the Licensed Product(s) in the CVT Territory; and 

  

	 	b)	an exclusive right and license to make, have made, use , offer for sale, sell and import the Licensed Product(s) in the CVT Territory 

 Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions
are designated as [*]. A complete version of this exhibit has been filed separately with the Securities and Exchange Commission. 

 5. Amendment of Sections 5.1(b)(3). Section 5.1(b)(3) of the License Agreement is hereby amended and replaced
in its entirety with the following new Section 5.1(b)(3): 
  

	 	(3)	Subsequent NDA Payments. In addition to the payment in Section 5.1(b)(2) above, CVT shall make the following payments to Roche: (a) within thirty (30) days of
the second approval of an NDA or equivalent in one of the Major Market Countries Nine Million United States Dollars (US$9,000,000.00); (b) within thirty (30) days of the approval of an NDA or equivalent in Japan Three Million United States
Dollars (US$3,000,000.00); and (c) within thirty (30) days of the approval of the first supplemental NDA for an indication other than Cardiovascular Indications in a Major Market Country or Japan Five Million United States Dollars
(US$5,000,000.00). 

 6. Amendment of Article IX. Article IX of the License Agreement is hereby amended and replaced in its entirety
with the following new Article IX: 
 Syntex retains the right to use the know-how encompassed in the Syntex Patents and Know-How for
non-commercial, research purposes only. CVT herewith grants to Syntex a non-exclusive, non-royalty right and license under any CVT patents and Know-How to exercise such right. 
 7. Amendment of Section 11.2. Section 11.2 of the License Agreement is hereby amended by deleting the phrase “for Cardiovascular Indications” from the last sentence. 
 8. Additional Payment. Within ten (10) days of the execution of this Fourth Amendment, CVT shall pay to Roche the amount of [*] United States Dollars
(US$[*]). 
 9. Full Force and Effect. This Fourth Amendment amends the terms of the Agreement and the Amendments and is deemed incorporated into, and
governed by all the other terms of, the Agreement and Amendments. In the event of any conflict between the terms of the Agreement and the Amendments and the terms of this Fourth Amendment, the terms of this Fourth Amendment shall govern. The
provisions of the Agreement, as amended by the Amendments and this Fourth Amendment, remain in full force and effect. 
 IN WITNESS WHEREOF,
the parties have executed this Fourth Amendment to be effective as of the Fourth Amendment Date. 
  

							
	Roche Palo Alto LLC	 	CV Therapeutics, Inc.
				
	 By:
	 	 /s/ Robert B. Stein
	 	By:	 	 /s/ Louis G. Lange, M.D., Ph.D.

	Name:	 	Robert B. Stein, M.D., Ph.D.	 	Name:	 	Louis G. Lange, M.D., Ph.D.
	Title:	 	President	 	Title:	 	Chairman & CEO

  

 [*] Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.Seventh Supplemental  Indenture

 Exhibit 4.1.1 

 CHESAPEAKE ENERGY CORPORATION 
 and

 the Subsidiary Guarantors named herein 
 7.5% SENIOR NOTES DUE 2014 
  

 SEVENTH SUPPLEMENTAL INDENTURE 
 DATED AS OF MAY 8, 2006 
  

 THE BANK OF NEW YORK TRUST COMPANY,
N.A. 
 as Trustee 
  

 THIS SEVENTH SUPPLEMENTAL INDENTURE, dated as of May 8, 2006 is among Chesapeake Energy Corporation,
an Oklahoma corporation (the “Company”), each of the parties identified under the caption “Subsidiary Guarantors” on the signature page hereto (the “Subsidiary Guarantors”) and The Bank of New York Trust
Company, N.A., as Trustee. 
 RECITALS 
 WHEREAS, the Company, the Subsidiary Guarantors a party thereto and the Trustee entered into an Indenture, dated as of May 27, 2004, as supplemented prior to the date hereof (the “Indenture”),
pursuant to which the Company has originally issued $300,000,000 in principal amount of 7.5% Senior Notes due 2014 (the “Notes”); and 
 WHEREAS, Section 9.01(3) of the Indenture provides that the Company, the Subsidiary Guarantors and the Trustee may amend or supplement the Indenture without notice to or consent of any Holder to reflect the
release of any Subsidiary Guarantor as provided for in the Indenture; and 
 WHEREAS, the Company has taken all actions required to effect
the release, pursuant to Sections 10.02 and 10.04 of the Indenture, of Oxley Petroleum Co. (“Oxley”), an Oklahoma limited partnership. 
 WHEREAS, all acts and things prescribed by the Indenture, by law and by the charter and the bylaws (or comparable constituent documents) of the Company, of the Subsidiary Guarantors and of the Trustee necessary to make this Seventh
Supplemental Indenture a valid instrument legally binding on the Company, the Subsidiary Guarantors and the Trustee, in accordance with its terms, have been duly done and performed; 
 NOW, THEREFORE, to comply with the provisions of the Indenture and in consideration of the above premises, the Company, the Subsidiary Guarantors and the
Trustee covenant and agree for the equal and proportionate benefit of the respective Holders of the Notes as follows: 
 ARTICLE 1

 Section 1.01. This Seventh Supplemental Indenture is supplemental to the Indenture and does and shall be deemed to form a
part of, and shall be construed in connection with and as part of, the Indenture for any and all purposes. 
 Section 1.02. This
Seventh Supplemental Indenture shall become effective immediately upon its execution and delivery by each of the Company, the Subsidiary Guarantors and the Trustee. 
  

 - 2 - 

 ARTICLE 2 
 Section 2.01. As a result of the dissolution of Oxley, the Company has taken all actions required to effect the release, pursuant to Section 10.04 of the Indenture, of Oxley as a Subsidiary Guarantor.
The notation on the Securities relating to the Guarantee shall be deemed to exclude the name of Oxley and the signature of an Officer of Oxley on its behalf. 
 ARTICLE 3 
 Section 3.01. Except as specifically modified herein, the Indenture and the
Notes are in all respects ratified and confirmed (mutatis mutandis) and shall remain in full force and effect in accordance with their terms with all capitalized terms used herein without definition having the same respective meanings
ascribed to them as in the Indenture. 
 Section 3.02. Except as otherwise expressly provided herein, no duties, responsibilities
or liabilities are assumed, or shall be construed to be assumed, by the Trustee by reason of this Seventh Supplemental Indenture. This Seventh Supplemental Indenture is executed and accepted by the Trustee subject to all the terms and conditions set
forth in the Indenture with the same force and effect as if those terms and conditions were repeated at length herein and made applicable to the Trustee with respect hereto. 
 Section 3.03. THE LAW OF THE STATE OF NEW YORK SHALL GOVERN AND BE USED TO CONSTRUE AND ENFORCE THIS SEVENTH SUPPLEMENTAL INDENTURE.

 Section 3.04. The parties may sign any number of copies of this Seventh Supplemental Indenture. Each signed copy shall be an
original, but all of such executed copies together shall represent the same agreement. 
 [NEXT PAGE IS SIGNATURE PAGE] 
  

 - 3 - 

 IN WITNESS WHEREOF, the parties hereto have caused this Seventh Supplemental Indenture to be duly
executed, all as of the date first written above. 
  

	
	
	 /s/ Aubrey K. McClendon

	Aubrey K. McClendon
	
	 Chief Executive Officer of the Company and
 of
the Subsidiaries listed below:

	
	Corporate Subsidiaries:
	
	CHESAPEAKE EAGLE CANADA CORP.
	 CHESAPEAKE ENERGY LOUISIANA
             CORPORATION

	CHESAPEAKE SOUTH TEXAS CORP.
	NOMAC DRILLING CORPORATION
	HODGES HOLDING COMPANY, INC.
	HODGES OILFIELD COMPANY
	HODGES TRUCKING COMPANY
	NOMAC 100 CORP.
	W.W. REALTY, INC.
	
	CHESAPEAKE OPERATING, INC.,
	On behalf of itself and, as general partner, the following limited partnerships:
	
	 CHESAPEAKE EXPLORATION LIMITED
             PARTNERSHIP

	CHESAPEAKE LOUISIANA, L.P.
	CHESAPEAKE SIGMA, L.P.
	
	CHESAPEAKE ENERGY MARKETING, INC.,
	On behalf of itself and, as general partner, the following limited partnerships:
	
	MIDCON COMPRESSION, L.P.
	
	Limited Liability Company Subsidiaries:
	
	CHESAPEAKE APPALACHIA, L.L.C.
	HAWG HAULING & DISPOSAL, L.L.C.
	CARMEN ACQUISITION, L.L.C.
	CHESAPEAKE ACQUISITION, L.L.C.
	CHESAPEAKE LAND COMPANY, L.L.C.
	CHESAPEAKE ORC, L.L.C.
	CHESAPEAKE ROYALTY

  

 - 4 - 

			
	 GOTHIC PRODUCTION, L.L.C.
 MC
MINERAL COMPANY, L.L.C.
 MAYFIELD PROCESSING, L.L.C.
  
 TRUSTEE:
  
 THE BANK OF NEW YORK TRUST COMPANY,
 N.A., as Trustee

		
	By:	 	 /s/ Linda Garcia

	Name:	 	Linda Garcia
	Title:	 	Assistant Vice President

  

 - 5 -

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00108-of-00352.parquet"}]]